**Pharmacological and non-pharmacological treatment of adults with ADHD: a meta-review**

Franco De Crescenzo a\*, Samuele Cortese b,c, Nicoletta Adamo d, and Luigi Janiri a.

a Institute of Psychiatry and Psychology, Catholic University of Sacred Heart, Rome, Italy.

b Department of Psychology, Developmental Brain-Behaviour Laboratory, University of Southampton, Highfield Campus, and Solent NHS Trust, Southampton, UK.

c Langone Medical Center, New York University Child Study Center, New York City, New York, USA.

d MRC Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.

**\*Corresponding author:** Franco De Crescenzo, Institute of Psychiatry and Psychology, Catholic University of Sacred Heart, Largo A. Gemelli 8, 00168, Rome, Italy. Tel: 0630154122. Email: decrescenzo.franco@gmail.com

**Key words:** Attention-Deficit/Hyperactivity Disorder; Adult; Treatment; Evidence-Based Medicine.

**Word counts:** 3409**ABSTRACT**

**Objectives:** Althoughless developed compared to the body or research on children with ADHD, evidence on the treatment of adults with ADHD is rapidly increasing. Here, we performed a meta-review of systematic reviews on the treatment of adults with ADHD, in order to inform best clinical practice.

**Methods:** Medline, PubMed, PsycInfo and Cochrane databases were searched from January 1st, 2010 to May 31st, 2016 for systematic reviews on the treatment of ADHD in adulthood. We build on these reviews to address clinically relevant questions.

**Results:**  We identified a total of 40 relevant systematic reviews. Psychostimulants -such as methylphenidate, dextroamphetamine, mixed amphetamine salts, and lisdexamphetamine-, and non-psychostimulants –such as atomoxetine-, have been the most studied agents. These medications overall are significantly more efficacious than placebo (standardized mean difference [SMD]: 0.45, 95% confidence interval [CI]: 0.37, 0.52), albeit less well accepted (odds ratio [OR]: 1.18, 95% CI: 1.02, 1.36) and tolerated (OR: 2.29, 95% CI: 1.97, 2.66). A comprehensive evidence-informed hierarchy of ADHD drugs based on their efficacy and tolerability is not yet available. There is a documented risk of misuse of prescription stimulants for the treatment of ADHD in adults, while the effects of pharmacological treatment for individuals with co-occurring ADHD and substance use disorder are still uncertain. The evidence for the efficacy and effectiveness of non-pharmacological treatments of ADHD in adults, as well as the combination of pharmacological and non-pharmacological strategies, is only preliminary.

**Conclusions:** Whileavailable evidenceaddressed mainly the efficacy and tolerability of psychostimulants and non-psychostimulants for ADHD core symptoms in the short term, we still need further empirical support for the non-pharmacological and multimodal treatments as well as for the hierarchy of efficacy of available pharmacological interventions. .

**INTRODUCTION**

Attention-Deficit/Hyperactivity Disorder (ADHD) is one of the most common neuropsychiatric conditions,1 with a pooled worldwide prevalence estimated at about 5% in school-aged children and persistence of impairing symptoms in adulthood in up to 65% of cases.1 The pooled estimated prevalence of ADHD (as categorical diagnosis) in adults is around 2.5%1

ADHD is characterised by a persistent and impairing pattern of inattention and/or hyperactivity/impulsivity. According to the current edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), at least five out of nine symptoms of inattention and/or hyperactivity/impulsivity are required for the diagnosis. Although, based on current diagnostic criteria, ADHD onset is by definition in childhood (more specifically, before the age of twelve), recent research suggests that, in some cases, it might appear *de novo* in adulthood.2 Other diagnostic criteria require that symptoms are present in more than one setting (e.g., academic, social, and occupational) and lead to functional impairment in various domains. DSM-5 defines three ADHD clinical presentations based on symptom profile: combined, predominantly inattentive and predominantly hyperactive/impulsive presentation. Changes from previous edition of the DSM (DSM-IV-TR) include, among others, the age of onset (now “prior to age of twelve”, before “prior to age of seven”), the count threshold for the diagnosis in adults (at least five symptoms of inattention and/or hyperactivity/impulsivity, rather than six as in children) and the inclusion of specific age-appropriate examples of ADHD symptoms in adults.

The International Classification of Disease (ICD-10) describes a syndrome, namely hyperkinetic disorder (HKD), which overlaps with the predominantly combined ADHD subtype in the DSM-IV. Specifically, the diagnosis of HKD requires both symptoms of inattention and hyperactivity/impulsivity.

The assessment of an adult referred for possible ADHD includes: 1) identifying symptoms and behaviours consistent with DSM-5 diagnostic criteria for ADHD; 2) considering age of onset of symptoms; 3) estimating functional impairment; 4) evaluating pervasiveness of symptoms; 5) identifying coexisting disorders; and 6) ruling out other psychiatric or somatic differential diagnoses. It is also important to record family history, to perform a physical and neurological examination and support the clinical judgment with questionnaires/rating scales. Guidelines from various countries agree on the importance of a clinical psychiatric interview in secondary care to confirm an ADHD diagnosis and start an appropriate treatment 3. The DIVA 2.0 interview (DIVA 2015), based on DSM-IV criteria, can be of help to guide clinicians in the diagnosis.4

The diagnosis of ADHD in adulthood is relatively straightforward when symptoms are clearly present and the diagnosis was previously made in childhood. However, if not established during childhood, the diagnosis of ADHD in adults can be difficult. Particularly important is to interview at least one adult informant (such as a parent or a close relative), who can give information about the behaviour of the patient as a child. As most adults have a recall bias it is difficult for them to recall the onset, severity and persistence of ADHD symptoms, and this makes it difficult to make a good assessment based only on the patients’ own report.5 Having another informant in addition to the patient can also help to prevent patients from assuming a manipulative response style, which can lead to over or underestimate symptoms or to obtain psychostimulants for non-medical use.6

Adult ADHD is often comorbid with other psychiatric disorders, such as depression, anxiety, substance use disorder, antisocial personality disorder, and/or somatic conditions, such as obesity.5 7 8 A large body of evidence shows that untreated adult ADHD leads to negative psychosocial consequences, including poor education, antisocial acts, marital difficulties, incarceration and lower socioeconomic status.1 8 Effective treatment of ADHD can help prevent these negative outcomes.5

The management of ADHD often requires a multimodal approach. This includes medications, such as psychostimulants (methylphenidate and amphetamine derivatives), non-stimulant medications (e.g., atomoxetine), and non-pharmacological interventions (such as behavioural therapies). Indeed, different countries can have licensed different medications and regulations may change between children/adolescents and adults. Extended- release clonidine and extended-release guanfacine have been approved by the FDA for the treatment of ADHD, but not specifically for adults. Other pharmacological options that have been used off-label include modafinil and a number of antidepressants (venlafaxine, bupropion, desipramine, paroxetine, nomifensine, reboxetine, and duloxetine).9

With regards to the treatment of ADHD in children and adolescents, a large body of research10 shows that ADHD medications are efficacious, at least in the short term, and generally well tolerated for ADHD core symptoms, although recently the quality of available evidence has been questioned.11 In terms of non-pharmacological interventions, a series of recent meta-analyses from the European ADHD Guidelines Group (EAGG)12 failed to find solid empirical support for their efficacy for ADHD core symptoms. However, the EAGG concluded that non-pharmacological treatments might still be valuable for the treatment of comorbid conditions such as oppositional-defiant, and emotional problems. The uncertainty regarding the role of non-pharmacological interventions in the management of ADHD is reflected in the discrepancy in current European guidelines, with the North American practice parameters13 suggesting medication as first choice, and the European guidelines recommending a pharmacological treatment only when behavioural interventions are not effective.14-16

Given that ADHD in adults has only been recently recognised, evidence on its treatment is overall less developed compared to childhood ADHD. However, the body of empirical research on the treatment of ADHD in adults has been rapidly increasing in the past few years. The aim of this paper is to perform a review of the literature focusing on recent systematic reviews and meta-analyses relevant to the pharmacological and non-pharmacological treatment of adult ADHD (the so called, meta-review), in order to assist clinicians in daily decision-making.

**METHODS**

We searched Medline, PubMed, PsycInfo and Cochrane databases from January 1st, 2010 to May 31st 2016 for systematic reviews on the pharmacological and non-pharmacological treatment of adults with ADHD. The Pubmed search syntax was as follows: (adhd OR ADHD OR attention-deficit/hyperactivity OR attention deficit) AND (meta-analy\* OR metaanaly\* OR systematic review\*). The syntax was adapted for other electronic databases. No language restrictions were applied. As in Huhn et al.,17 full articles were examined by one author (FDC), and two other authors (SC, NA) independently examined a random sample of 20% of the potentially eligible references. Initial disagreement in the selection of pertinent papers was resolved with discussion by the three authors. We also searched the most recent guidelines/recommendations (last ten years) on adult ADHD to relate these recommendations to available evidence. References from relevant papers were examined to determine if any relevant studies had been missed during the database searches.

**RESULTS**

We initially identified 635 potentially relevant references. After removing non-pertinent references based on title/abstract or full text, we retained a total of 40 pertinent papers (see Table 1). We build on these retrieved reviews to address the following clinically relevant questions:

* What is the evidence base for the efficacy of pharmacological treatments of ADHD in adults?
* What is the evidence base for the acceptability and tolerability of pharmacological treatments of ADHD in adults?
* Is there an evidence based recommended hierarchy in the choice of medications for ADHD in adults?
* What is the evidence base for the efficacy of non-pharmacological treatments of ADHD in adults?
* What is the evidence base for the efficacy of multimodal treatments of ADHD in adults?
* How should adults with ADHD and co-occurring substance abuse be treated?

**Table 1. Characteristics of the systematic reviews included in the meta-review.**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Study** | **Type of studies included** | **Study design** | **Population** | **Intervention** | **Comparison** | **Primary outcomes** |
| *Arnold 201518* | Observational studies | Systematic review | Children, adolescents and adults | Any treatment | Any | Long-term outcomes (>/=2 years) |
| *Arnold 201519* | Observational studies | Systematic review | 731668 Children, adolescents and adults  | Any treatment | Any | Long-term academic achievement |
| *Asherson 201420* | RCTs | Pooled analysis of sponsored trials | 1413 Adults | Atomoxetine | Placebo | Symptoms of ADHD |
| *Asherson 201521* | RCTs | Pooled analysis of sponsored trials | 829 Adults | Atomoxetine | Placebo | Emotional control |
| *Bangs 201422* | RCTs | Meta-analysis | 7248 Children, adolescents and adults  | Atomoxetine | Placebo | Suicide-related behavior or ideation |
| *Barkla 201523* | Animal and human studies | Systematic review | Adolescents and adults with substance abuse | Methylphenidate,Atomoxetine, Dexamphetamine, Lisdexamfetamine, | Any | Side effects of combining ADHD medication with alcohol and drugs of abuse |
| *Benson 201524* | Observational studies | Meta-analysis | College students with and without ADHD | Stimulant medications | Any | Rates of stimulant misuse |
| *Bruce 201425* | Non-randomised clinical trials | Systematic review | Young drivers | Behavioural interventions | Any | Driving performance |
| *Buoli 20169* | Any | Systematic review | Adults | Alternative pharmacological treatments (excluding Methylphenidate and Atomoxetine) | Any | Efficacy and tolerability |
| *Bushe 201626* | RCTs | Meta-analysis | Adults | Atomoxetine and osmotic release oral system Methylphenidate | Placebo | Efficacy and acceptability |
| *Cairncross 201627* | Clinical trials | Meta-analysis | 178 Children, adolescents and adults  | Mindfulness-based therapies | Any | Symptoms of ADHD |
| *Caisley 201228* | Observational studies | Systematic review | Adults | Any pharmacological treatment | Any | Adherence |
| *Camporeale 201329* | RCTs | Pooled analysis of sponsored trials | 3314 Adults | Atomoxetine | Placebo | Sexual and genito-urinary adverse events |
| *Castells 201330* | RCTs | Meta-analysis | 2496 Adults | Methylphenidate | Placebo | All-cause treatment discontinuation |
| *Castells 201131* | RCTs | Meta-analysis | 1091 Adults | Amphetamines | Any | Efficacy and tolerability |
| *Castells 201132* | RCTs | Meta-analysis | 2045 Adults | Methylphenidate | Placebo | Symptoms of ADHD |
| *Chandler 201333* | Clinical trials | Systematic review | 566 Adolescents and adults | Cognitivebehavioural therapy | Any | Symptoms of ADHD |
| *Coghill 201334* | Observational studies and clinical trials | Systematic review | Children, adolescents and adults, healthy and with ADHD | Long-acting Methylphenidate formulations | Long-acting Methylphenidate formulations | Comparative efficacy of the long-acting formulations available |
| *Coghill 201435* | Observational studies and clinical trials | Systematic review | Children, adolescents and adults  | Lisdexamfetamine | Any | Safety |
| *Cunill 201336* | RCTs | Meta-analysis | 3375 Adults | Atomoxetine | Placebo | All-cause treatment discontinuation |
| *Cunill 201537* | RCTs | Meta-analysis | 1271 Children, adolescents and adults with co-occurring ADHD and substance use disorder | Any pharmacological treatment | Placebo | Symptoms of ADHD, all-cause treatment discontinuation, drug abstinence |
| *Cunill 201638* | RCTs | Meta-analysis | 9952 Adults | Any pharmacological treatment | Placebo | All-cause treatment discontinuation |
| *Frank 201539* | Observational studies and clinical trials | Systematic review | Children, adolescents and adults | Amphetamine, Methylphenidate, Atomoxetine, Guanfacine, Clonidine | Any | Adherence and side effects |
| *Fredriksen 201340* | Observational studies and clinical trials | Systematic review | Adults | Amphetamine, Methylphenidate, Atomoxetine | Any | Efficacy and tolerability |
| *Fridman 201541* | RCTs | Meta-analysis | 6770 Children, adolescents and adults | Lisdexamfetamine, Atomoxetine, osmotic-release oral system Methylphenidate | Placebo | Symptoms of ADHD |
| *Ganizadeh 201342* | Clinical trials | Systematic review | Children, adolescents and adults | Aripiprazole | Any | Efficacy and tolerability |
| *Ganizadeh 201343* | Clinical trials | Systematic review | Children, adolescents and adults | Magnesium | Any | Efficacy and tolerability |
| *Ganizadeh 201544* | Clinical trials | Systematic review | Children, adolescents and adults | Reboxetine | Any | Efficacy and tolerability |
| *Gobbo 201445* | RCTs | Systematic review | 283 Adults | Methylphenidate, mixed Amphetamine salts, Atomoxetine and Lisdexamfetamine | Any | Driving performance |
| *Jensen 201646* | Clinical trials | Meta-analysis | 85 Adults | Cognitive behavioural therapy | Treatment as usual | Quality of life and adverse events |
| *Linderkamp 201147* | Clinical trials | Meta-analysis | Adults | Any pharmacological treatment, psychotherapeutic therapies | Any | Efficacy |
| *Maneeton 201448* | RCTs | Meta-analysis | 146 Children, adolescents and adults | Bupoprion | Methylphenidate | Efficacy, acceptability and tolerability |
| *Maneeton 201449* | RCTs | Meta-analysis | 806 Adults | Lisdexamfetamine | Placebo | Efficacy, acceptability and tolerability |
| *Matsui 201650* | Clinical trials | Systematic review | 499 Children, adolescents and adults | Buspirone | Any | Efficacy, acceptability and tolerability |
| *Mick 201251* | RCTs | Meta-analysis | 2144 Adults | Methylphenidate, mixed Amphetamine salts, and Lisdexamfetamine | Placebo | Heart rate and blood pressure |
| *Shaw 201252* | Observational studies and clinical trials | Systematic review | Children, adolescents and adults | Any pharmacological, non-pharmacological, or multimodal | Control, proband, placebo, untreated, no treatment, pretreatment, comparator, follow-up, normal | Long-term outcomes (>/=2 years) |
| *Tamminga 201653* | RCTs | Meta-analysis | 1611 Children, adolescents and adults | Methylphenidate | Placebo | Executive functions |
| *Vidal-Estrada 201254* | Clinical trials | Systematic review | 508 Children, adolescents and adults | Cognitive behavioural therapy, Metacognitive therapy, Dialectical behavior therapy, Coaching, Cognitive remediation | Any | Symptoms of ADHD |
| *Westover 201255* | Observational studies | Systematic review | Children, adolescents and adults with prescription stimulant use | Methylphenidate, mixed Amphetamine salts, Dextroamphetamine | Any | Hard cardiovascular outcomes |
| *Weyandt 201456* | Clinical trials | Systematic review | Adolescents and adults | Lisdexamfetamine, Methylphenidate, Amphetamines, and mixed-Amphetamine salts | Any | Efficacy and stimulant misuse |

ADHD = Attention Deficit/ Hyperactivity Disorder; RCTs = Randomised Controlled Trials..

**- What is the evidence base for the efficacy of pharmacological treatments of ADHD in adults?**

Overall, pharmacological treatments have been found to be efficacious, at least in the short term, for reducing ADHD symptoms in adults, when compared with placebo (standardized mean difference [SMD]: 0.45, 95% confidence interval [CI]: 0.37, 0.52).38 Psychostimulants are the most commonly researched medications for ADHD not only in children and adolescents, but also in adults.

The British Association of Psychopharmacology (BAP) and the NICE guidelines, recommend methylphenidate as the first-line pharmacological option in adult ADHD.14 16 A systematic review by Castells et al.,32 suggests that methylphenidate is significantly more efficacious than placebo in reducing ADHD symptoms, with a moderately large effect size (SMD: 0.49, 95% CI: 0.34, 0.64) in the short term, independently on the type of formulation used, and in a dose-dependent fashion.

With regards to the type of formulation, immediate-release methylphenidate has shown good efficacy on the symptoms of hyperactivity, impulsivity and inattention (SMD: 0.54, CI: 0.41, 0.67).32 A recent meta-analysis has confirmed the efficacy of methylphenidate also in its sustained-release formulation in adult ADHD, with superiority versus placebo (SMD: 0.51; 95% CI: 0.4, 0.63).26 Methylphenidate, regardless of the type of formulation, has also been found to be significantly more efficacious than placebo in reducing executive dysfunctions, that are often associated with ADHD (response inhibition: SMD: 0.4, 95% CI: 0.22, 0.58; working memory SMD: 0.24, 95% CI: 0.0, 0.48; sustained attention SMD: 0.42, 95% CI: 0.26, 0.59).53

Several studies have recently proved the efficacy of other psychostimulants for adult ADHD, with large effect sizes.31 41 49 A Cochrane review found a significant improvement, compared to placebo, in symptom severity for any amphetamine derivative (SMD: -0.73, 95% CI: -0.96, -0.51), dextroamphetamine (SMD: -0.6, 95% CI: -1, -0.2), mixed amphetamine salts (SMD: -0.73, 95% CI: -0.96, -0.51), and lisdexamphetamine (SMD: -0.8, 95% CI: -1.07, -0.53).31 A more recent meta-analysis on lisdexamphetamine confirmed a large effect over placebo on ADHD symptoms (SMD: -0.97, 95% CI: -1.15, -0.78).49

Atomoxetine, a non-psychostimulant pharmacological treatment, was found to be more efficacious than placebo in reducing ADHD symptom severity, both according to clinician (SMD: 0.40, 95% CI: 0.48, 0.32) or patient (SMD: 0.33, 95% CI: 0.43, 0.23) ratings 36. Moreover, two studies20 21 found a significant improvement in the clinical global impressions of ADHD-severity for atomoxetine versus placebo in both short (34.8% versus 22.3%) and long-term (43.4% versus 28.0%) analyses. Atomoxetine was found to be superior to placebo, 26 albeit with smaller effect sizes (SMD: 0.47, 95% CI: 0.37; 0.56) than those previously reported for amphetamines, but not smaller than those obtained for the methylphenidate (see above). However, no significant difference between atomoxetine and sustained release methylphenidate was found in efficacy (SMD: -0.05, 95% CI: -0.17, 0.07). 26 The non-inferiority of atomoxetine versus methylphenidate, for the reduction of ADHD symptoms in adults, was demonstrated also in a meta-analysis of studies with a direct comparison, which resulted in a non-significant difference in favour of methylphenidate (absolute difference: −0.9%, 95% CI: −9.2%, 7.5%).57 Indeed, the effect size for methylphenidate seems to be smaller in adults than that quoted for children and adolescents, while the effect size for the amphetamines is not.

Available systematic reviews found only preliminary evidence (few studies with a low sample size and methodological issues), to support the efficacy of bupoprion,48 buspirone,50 aripiprazole,42 magnesium,43 and reboxetine44 in adults with ADHD.

**- What is the evidence base for the acceptability and tolerability of pharmacological treatments of ADHD in adults?**

Pharmacological treatments overall, compared with placebo in adults with ADHD, seem to be slightly less well accepted (OR: 1.18, 95% CI: 1.02, 1.36) and less well tolerated (OR: 2.29, 95% CI: 1.97, 2.66).38 Mean adherence rate for all pharmacological treatments in adult ADHD in retrospective naturalistic studies ranged from 52% to 87%.28 In a recent meta-analysis, adults were found to have a higher chance of discontinuation in the long term for all pharmacological treatments of ADHD (79.7%) compared to children (48.8%) and adolescents (72.1%).39 Some authors endorse the pro re nata (PRN) regimen (i.e., administration of the medicine only as required) in order to improve adherence by improving autonomy of patients, reducing side effects and saving costs.28

Compared to placebo, the acceptability of methylphenidate in adults with ADHD did not significantly differ in randomised controlled studies (RCTs) (OR: 1.19, 95% CI: 0.82, 1.74).30 However, the osmotic-controlled release oral delivery system (OROS) methylphenidate (a sustained-release formulation) can be less acceptable than placebo (OR: 1.68, 95% CI: 1.25, 2.28). 26 The tolerability of methylphenidate, measured as adverse-event induced discontinuation, was found to be significantly worse than placebo (OR: 2.68, 95% CI: 1.81, 3.98).30

The retention in treatment in randomised clinical trials did not differ from placebo for any amphetamine derivative (risk ratio [RR]: 1.06, 95% CI: 0.96, 1.18), dexamphetamine (RR: 0.96, 95% CI: 0.8, 1.14), and lisdexamphetamine (RR: 0.99, 95% CI: 0.88, 1.11). 31 However, mixed amphetamine salts increased the retention in treatment compared to placebo (RR: 1.19, 95% CI: 1.06, 1.35). The tolerability was lower for any amphetamine derivative versus placebo (RR: 3.03, 95% CI: 1.52, 6.05), although this estimate is likely to be imprecise, because adverse events are not always well reported in clinical studies. 31

In a meta-analysis on 2665 adults with ADHD, the use of psychostimulants was significantly correlated with a mean increase in resting heart rate of 5.7 beat per minute and an increased systolic blood pressure of mean 2 mmHg.51 This meta-analysis, however, has found a low rate of clinically significant cardiovascular events, including hypertension and tachycardia. Nonetheless, another systematic review identified a probable increased risk for transient ischemic attack and sudden death/ventricular arrhythmia in adult ADHD treated with stimulants, although the magnitude and clinical impact of this increased risk need further clarification.55

Other common non-serious adverse events for stimulants include decreased appetite and insomnia,35 39 which can often be a cause of discontinuation.28 NICE guidelines14 recommend to closely monitor weight, heart rate and blood pressure and to perform a baseline ECG when indicated based on the clinical history.

Bushe et al.26, found no difference between atomoxetine versus sustained-release methylphenidate in acceptability (SMD: 0.85, 95% CI: 0.61, 1.2), while they found atomoxetine to be less acceptable than placebo (OR: 1.33, 95% CI: 1.09, 1.63), in accordance with Cunill et al.36 (OR: 1.39, 95% CI: 1.17, 1.64). Atomoxetine, compared to placebo, was found to have more sexual and genito-urinary side effects (decreased libido, dysuria, urinary hesitation, urine flow decreased, ejaculation and erectile dysfunctions) in adult males with ADHD.29 We do not have evidence of significantly greater risk of suicide-related events and suicidal ideation for atomoxetine over placebo in adults with ADHD.22

Randomised controlled trials on medications in adult ADHD are mostly short-term and at the present time, the evidence on long-term effects of medications is preliminary -with no available pooled effect size. However, improved outcomes for treated than untreated adults with ADHD have ben reported.18 19 40 52

**- Is there an evidence based recommended hierarchy in the choice of medications for ADHD in adults?**

According to the NICE14, methylphenidate is the pharmacological treatment with the most solid evidence base and should be considered as first in adult ADHD. Other psychostimulants and atomoxetine should be considered as a second choice. Immediate or sustained release formulations should be tailored on the single patient, while PRN regimen can be considered as well.

To date, there are no published evidence-based hierarchies on the efficacy and acceptability of all the most common available pharmacological treatments for ADHD in children as well as in adults. However, from the reviews mentioned above, the effect sizes on efficacy versus placebo seem higher for amphetamines than for methylphenidate. A recent network meta-analysis26 has focused on the comparative efficacy and tolerability of atomoxetine, OROS methylphenidate and placebo. This meta-analysis concluded that atomoxetine did not differ significantly from OROS methylphenidate neither in efficacy, nor in acceptability. However, the meta-analysis failed to include other agents available for the treatment of ADHD.

**-What is the evidence base for the efficacy of non-pharmacological treatments of ADHD in adults?**

Addressing behavioural, psychological, educational and occupational needs is recognised to be essential in the treatment of adults with ADHD. 14 However, while in children and adolescents there is evidence that non-pharmacological treatments are efficacious to address disorders and impairments associated with ADHD (e.g., oppositional behaviours and poor parenting via behavioural intervention, and working memory impairment via working memory training), in adults the value of non-pharmacological interventions is less clear. NICE guidelines recommend using pharmacological treatment in adult ADHD as the first line choice, but they also point out that a psychological treatment should be considered, if it is preferred by the patient.14 However current evidence is mixed and inconclusive.

Recent systematic reviews have shown some positive effects on symptoms for the treatment of adult ADHD for mindfulness,27 dialectical behaviour therapy,33 54 and cognitive behavioural therapy (CBT),33 but they were not necessarily based on randomised evidence. Therefore, these approaches still need further research before being possibly integrated in standard practice. In a recent meta-analysis of studies conducted in adults with ADHD, CBT was found efficacious in reducing patient-rated symptoms (SMD: -1.0, 95% CI: -1.5, -0.5), but not clinician-rated symptoms.46 Of note, behavioural interventions have been found to improve driving performances in adults with ADHD.25

**- What is the evidence base for the efficacy of multimodal treatments of ADHD in adults?**

There is a very weak evidence that multimodal treatment is effective in children and adolescents with ADHD.14 In adults with ADHD, two single studies on methylphenidate added on highly-structured group cognitive behavioural therapy versus non-specific clinical management, provided discordant results.58 59 However, there is no evidence from systematic reviews, so that this issue needs to be further explored.18 47 52

**-** **How should adults with ADHD and co-occurring substance abuse be treated?**

Whilst there is evidence, from observational prospective studies, showing that children and adolescents with ADHD are at higher risk of long-term substance abuse compared to individuals without ADHD, there is limited evidence on the management of ADHD with co-occurring substance use.60

Cunill et al,37 in a systematic review of 1271 individuals with co-occurring ADHD and substance use disorder, found that pharmacological treatments were efficacious in treating ADHD symptoms (OR: 1.93, 95% CI: 1.4, 2.66), but were not efficacious on drug abstinence. Another study concluded that there is no evidence of serious side effects in adolescents and adults when ADHD medications are combined with alcohol and drugs of abuse;23 however, the limited number of studies reviewed (N= 20), both in animals and humans, suggests that caution is needed when interpreting the results of this systematic review. We also note that college students with ADHD have a rate of misuse of prescription stimulants around 17%.24 56 Immediate-release stimulants seem to be more likely to be misused than the sustained-release ones. A diagnosis of ADHD is highly correlated to stimulant medication misuse (OR: 4.68, 95% CI: 1.02, 21.44).24 Moreover, in college students with ADHD, a medical history positive for substance use is associated with higher rate of misuse of prescription stimulants.24

At present, individuals with co-occurring ADHD and substance abuse should be treated preferably with an integrated approach, including psychoeducation, coaching, cognitive behavioural therapy and non-stimulant medications or sustained-release stimulants.60

We did not find any systematic review focusing on the treatment of adults with ADHD and other comorbidities, which should be further studied in future.

**CONCLUSIONS**

Although, initially, ADHD was considered as only a disorder of childhood, in the last few years it has been possible to definitely validate ADHD in adulthood. 5

The diagnosis is clinical, and should be based, when possible, on information gathered from the patient and corroborated by another source. It is reasonable for clinicians in primary care to refer patients to secondary care for a reliable diagnosis and for the treatment management. Pharmacological treatment may be considered the first choice and methylphenidate the first-line option (for the number of studies and participants collected). Amphetamines seem to have higher efficacy from the RCTs, but this result should be taken cautiously as we still do not have a clear hierarchy of medications for both efficacy and safety and due to paucity of head to head studies it is premature to provide any firm recommendation. Non-stimulant medications or sustained-release stimulants could be considered for individuals at risk of prescription stimulants misuse. Non-pharmacological treatments can be used as add-on to pharmacological treatment, but while we have evidence of efficacy in children and adolescents, we do not have any evidence of efficacy of multimodal treatments in adults. Subsequently, patients can be followed up in primary care, although in a shared care way, and both subjective and objective measurements can be of help at this stage to monitor the clinical condition. In the long-term it is important to weigh the benefits of medication against all the possible side effects, to check the risk of non-medical use of prescription stimulants and to reconsider periodically the treatment options.

In terms of evidence base, whilst current studies support the efficacy and, overall, the good tolerability of psychostimulants and non-psychostimulants for ADHD core symptoms in the short term, further evidence is needed to understand how available medications rank in terms of efficacy/tolerability, their long terms effects, and the added value of combining pharmacological and non pharmacological treatments.

**ACKNOWLEDGMENTS**

None.

**COMPETING INTERESTS**

Dr. Cortese has received grant or research support from the Solent National Health Service (NHS) Trust, UK. He has received honorarium and travel expenses from the Association for Child and Adolescent Mental Health (ACAMH).

**REFERENCES**

1. Faraone SV, Asherson P, Banaschewski T, et al. Attention-deficit/hyperactivity disorder. Nature reviews Disease primers 2015;**1**:15020.

2. Moffitt TE, Houts R, Asherson P, et al. Is Adult ADHD a Childhood-Onset Neurodevelopmental Disorder? Evidence From a Four-Decade Longitudinal Cohort Study. The American journal of psychiatry 2015;**172**(10):967-77.

3. Seixas M, Weiss M, Muller U. Systematic review of national and international guidelines on attention-deficit hyperactivity disorder. Journal of psychopharmacology (Oxford, England) 2012;**26**(6):753-65.

4. Pettersson R, Soderstrom S, Nilsson KW. Diagnosing ADHD in Adults: An Examination of the Discriminative Validity of Neuropsychological Tests and Diagnostic Assessment Instruments. Journal of attention disorders 2015.

5. Thapar A, Cooper M. Attention deficit hyperactivity disorder. Lancet (London, England) 2016;**387**(10024):1240-50.

6. Chen LY, Crum RM, Strain EC, et al. Patterns of concurrent substance use among adolescent nonmedical ADHD stimulant users. Addictive behaviors 2015;**49**:1-6.

7. Klein M, van der Voet M, Harich B, et al. Converging evidence does not support GIT1 as an ADHD risk gene. American journal of medical genetics Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 2015.

8. Klein RG, Mannuzza S, Olazagasti MA, et al. Clinical and functional outcome of childhood attention-deficit/hyperactivity disorder 33 years later. Archives of general psychiatry 2012;**69**(12):1295-303.

9. Buoli M, Serati M, Cahn W. Alternative pharmacological strategies for adult ADHD treatment: a systematic review. Expert review of neurotherapeutics 2016;**16**(2):131-44.

10. Taylor E. Uses and misuses of treatments for ADHD. The second Birgit Olsson lecture. Nordic journal of psychiatry 2014;**68**(4):236-42.

11. Storebo OJ, Ramstad E, Krogh HB, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). The Cochrane database of systematic reviews 2015;**11**:CD009885.

12. Sonuga-Barke EJ, Brandeis D, Cortese S, et al. Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. The American journal of psychiatry 2013;**170**(3):275-89.

13. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry 2007;**46**(7):894-921.

14. (NICE) NIfHaCE. Attention deficit hyperactivity disorder: diagnosis and management NICE guidelines [CG72] [Available from: <https://www.nice.org.uk/guidance/cg72>].

15. Taylor E, Dopfner M, Sergeant J, et al. European clinical guidelines for hyperkinetic disorder -- first upgrade. European child & adolescent psychiatry 2004;**13 Suppl 1**:I7-30.

16. Bolea-Alamanac B, Nutt DJ, Adamou M, et al. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. Journal of psychopharmacology (Oxford, England) 2014;**28**(3):179-203.

17. Huhn M, Tardy M, Spineli LM, et al. Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: a systematic overview of meta-analyses. JAMA psychiatry 2014;**71**(6):706-15.

18. Arnold LE, Hodgkins P, Caci H, et al. Effect of treatment modality on long-term outcomes in attention-deficit/hyperactivity disorder: a systematic review. PloS one 2015;**10**(2):e0116407.

19. Arnold LE, Hodgkins P, Kahle J, et al. Long-Term Outcomes of ADHD: Academic Achievement and Performance. Journal of attention disorders 2015.

20. Asherson P, Bushe C, Saylor K, et al. Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: an integrated analysis of the complete database of multicenter placebo-controlled trials. Journal of psychopharmacology (Oxford, England) 2014;**28**(9):837-46.

21. Asherson P, Stes S, Nilsson Markhed M, et al. The effects of atomoxetine on emotional control in adults with ADHD: An integrated analysis of multicenter studies. European psychiatry : the journal of the Association of European Psychiatrists 2015;**30**(4):511-20.

22. Bangs ME, Wietecha LA, Wang S, et al. Meta-analysis of suicide-related behavior or ideation in child, adolescent, and adult patients treated with atomoxetine. Journal of child and adolescent psychopharmacology 2014;**24**(8):426-34.

23. Barkla XM, McArdle PA, Newbury-Birch D. Are there any potentially dangerous pharmacological effects of combining ADHD medication with alcohol and drugs of abuse? A systematic review of the literature. BMC psychiatry 2015;**15**:270.

24. Benson K, Flory K, Humphreys KL, et al. Misuse of stimulant medication among college students: a comprehensive review and meta-analysis. Clinical child and family psychology review 2015;**18**(1):50-76.

25. Bruce C, Unsworth C, Tay R. A systematic review of the effectiveness of behavioural interventions for improving driving outcomes in novice drivers with attention deficit hyperactivity disorder (ADHD). The British Journal of Occupational Therapy 2014;**77**(7):348-57.

26. Bushe C, Day K, Reed V, et al. A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients. Journal of psychopharmacology (Oxford, England) 2016;**30**(5):444-58.

27. Cairncross M, Miller CJ. The Effectiveness of Mindfulness-Based Therapies for ADHD: A Meta-Analytic Review. Journal of attention disorders 2016.

28. Caisley H, Muller U. Adherence to medication in adults with attention deficit hyperactivity disorder and pro re nata dosing of psychostimulants: a systematic review. European psychiatry : the journal of the Association of European Psychiatrists 2012;**27**(5):343-9.

29. Camporeale A, Day KA, Ruff D, et al. Profile of sexual and genitourinary treatment-emergent adverse events associated with atomoxetine treatment: a pooled analysis. Drug safety 2013;**36**(8):663-71.

30. Castells X, Cunill R, Capella D. Treatment discontinuation with methylphenidate in adults with attention deficit hyperactivity disorder: a meta-analysis of randomized clinical trials. European journal of clinical pharmacology 2013;**69**(3):347-56.

31. Castells X, Ramos-Quiroga JA, Bosch R, et al. Amphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults. The Cochrane database of systematic reviews 2011(6):CD007813.

32. Castells X, Ramos-Quiroga JA, Rigau D, et al. Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: A meta-regression analysis. CNS drugs 2011;**25**(2):157-69.

33. Chandler ML. Psychotherapy for adult attention deficit/hyperactivity disorder: a comparison with cognitive behaviour therapy. Journal of psychiatric and mental health nursing 2013;**20**(9):814-20.

34. Coghill D, Banaschewski T, Zuddas A, et al. Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies. BMC psychiatry 2013;**13**:237.

35. Coghill DR, Caballero B, Sorooshian S, et al. A systematic review of the safety of lisdexamfetamine dimesylate. CNS drugs 2014;**28**(6):497-511.

36. Cunill R, Castells X, Tobias A, et al. Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression. Pharmacoepidemiology and drug safety 2013;**22**(9):961-9.

37. Cunill R, Castells X, Tobias A, et al. Pharmacological treatment of attention deficit hyperactivity disorder with co-morbid drug dependence. Journal of psychopharmacology (Oxford, England) 2015;**29**(1):15-23.

38. Cunill R, Castells X, Tobias A, et al. Efficacy, safety and variability in pharmacotherapy for adults with attention deficit hyperactivity disorder: a meta-analysis and meta-regression in over 9000 patients. Psychopharmacology 2016;**233**(2):187-97.

39. Frank E, Ozon C, Nair V, et al. Examining why patients with attention-deficit/hyperactivity disorder lack adherence to medication over the long term: a review and analysis. The Journal of clinical psychiatry 2015;**76**(11):e1459-68.

40. Fredriksen M, Halmoy A, Faraone SV, et al. Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: a review of controlled and naturalistic studies. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2013;**23**(6):508-27.

41. Fridman M, Hodgkins PS, Kahle JS, et al. Predicted effect size of lisdexamfetamine treatment of attention deficit/hyperactivity disorder (ADHD) in European adults: Estimates based on indirect analysis using a systematic review and meta-regression analysis. European psychiatry : the journal of the Association of European Psychiatrists 2015;**30**(4):521-7.

42. Ghanizadeh A. Systematic review of clinical trials of aripiprazole for treating attention deficit hyperactivity disorder. Neurosciences (Riyadh, Saudi Arabia) 2013;**18**(4):323-9.

43. Ghanizadeh A. A systematic review of magnesium therapy for treating attention deficit hyperactivity disorder. Archives of Iranian medicine 2013;**16**(7):412-7.

44. Ghanizadeh A. A systematic review of reboxetine for treating patients with attention deficit hyperactivity disorder. Nordic journal of psychiatry 2015;**69**(4):241-8.

45. Gobbo MA, Louza MR. Influence of stimulant and non-stimulant drug treatment on driving performance in patients with attention deficit hyperactivity disorder: a systematic review. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2014;**24**(9):1425-43.

46. Jensen CM, Amdisen BL, Jorgensen KJ, et al. Cognitive behavioural therapy for ADHD in adults: systematic review and meta-analyses. Attention deficit and hyperactivity disorders 2016;**8**(1):3-11.

47. Linderkamp F, Lauth G. Efficacy of pharmacological versus psychotherapeutic therapies in adults with attention deficit/hyperactivity disorder (ADHD): An empirical meta-analysis. Verhaltenstherapie 2011;**21**(4):229-38.

48. Maneeton N, Maneeton B, Intaprasert S, et al. A systematic review of randomized controlled trials of bupropion versus methylphenidate in the treatment of attention-deficit/hyperactivity disorder. Neuropsychiatric disease and treatment 2014;**10**:1439-49.

49. Maneeton N, Maneeton B, Suttajit S, et al. Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD. Drug design, development and therapy 2014;**8**:1685-93.

50. Matsui Y, Matsunaga S, Matsuda Y, et al. Azapirones for Attention Deficit Hyperactivity Disorder: A Systematic Review. Pharmacopsychiatry 2016.

51. Mick E, McManus DD, Goldberg RJ. Meta-analysis of increased heart rate and blood pressure associated with cns stimulant treatment of adhd in adults. European Neuropsychopharmacology Jul 2012(Pagination):No Pagination Specified.

52. Shaw M, Hodgkins P, Caci H, et al. A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. BMC medicine 2012;**10**:99.

53. Tamminga HG, Reneman L, Huizenga HM, et al. Effects of methylphenidate on executive functioning in attention-deficit/hyperactivity disorder across the lifespan: a meta-regression analysis. Psychological medicine 2016:1-17.

54. Vidal-Estrada R, Bosch-Munso R, Nogueira-Morais M, et al. Psychological treatment of attention deficit hyperactivity disorder in adults: a systematic review. Actas espanolas de psiquiatria 2012;**40**(3):147-54.

55. Westover AN, Halm EA. Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review. BMC cardiovascular disorders 2012;**12**:41.

56. Weyandt LL, Oster DR, Marraccini ME, et al. Pharmacological interventions for adolescents and adults with ADHD: stimulant and nonstimulant medications and misuse of prescription stimulants. Psychology research and behavior management 2014;**7**:223-49.

57. Hazell PL, Kohn MR, Dickson R, et al. Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis. Journal of attention disorders 2011;**15**(8):674-83.

58. Philipsen A, Jans T, Graf E, et al. Effects of Group Psychotherapy, Individual Counseling, Methylphenidate, and Placebo in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial. JAMA psychiatry 2015;**72**(12):1199-210.

59. Emilsson B, Gudjonsson G, Sigurdsson JF, et al. Cognitive behaviour therapy in medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial. BMC psychiatry 2011;**11**:116.

60. Matthys F, Stes S, van den Brink W, et al. Guideline for screening, diagnosis and treatment of ADHD in adults with substance use disorders. International Journal of Mental Health and Addiction 2014;**12**(5):629-47.